Company mailbox

销售热线 021-50680557
Your current position: Home > About > Company Profile
公司简介 / Company Profile

Shanghai Liangrun biomedicine technology co.,Ltd. was established in Shanghai Free Trade Zone on Sep. 9th 2013, which is a national high-tech enterprise with a registered capital of 58.82 million yuan. Shanghai Liangrun focuses on the early screening and early diagnosis of major deaths such as cancer, Alzheimer's disease, and acute infectious diseases, and is committed to the innovative development and integration of reagents, key raw materials and automatic instruments.


Shanghai Liangrun owns an 800-square-meter scientific research laboratory, a 2,000-square-meter GMP standard modern factory, and an annual production capacity of more than 50 million diagnostic reagents. We have innovative R&D and clinical translation teams leading by 30 masters and doctors and for the core members they all have at least 10 years of industry experience.


We’ve developed the pioneering CST4 marker for gastrointestinal cancer detection the first time internationally, which obtained the certificates of NMPA in China and CE in EU in 2017, and currently this product obtained approvals for sale on the market in 5 provinces in China. The new maker CST1 of esophageal cancer is under clinical research. The R&D of the world’s first blood testing exosome product (exosome Tau/p-Tau, Αβ40/αβ42) for early screening of early Alzheimer's Disease (AD) has been successfully completed and now we are preparing the clinical registration trials world wild.


The Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Test Kit (Colloidal Gold) developed by Shanghai Liangrun is in the “white list” of the China’s Medical Insurance Chamber of Commerce for export. Now it has the registration certificates in 27 countries of EU, Russia, United Kingdom, Italy, Brazil, Singapore, Malaysia, Turkey, Peru, and Philippines, and has been exported to dozens of countries e.g. Europe, United States, Japan, Brazil, Russia, Malaysia, Singapore, Egypt, Italy and Ecuador. New products such as Novel Coronavirus (2019-nCoV) Antigen Rapid Test Kit (Colloidal Gold) and Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit (Colloidal Gold) will be launched soon.


A total of 25 national invention patents have been applied, 13 of which have been authorized, and another 7 invention patents are under application. We have 5 domestic or international trademarks. We’ve discovered, verified and launched the world's first gastrointestinal cancer serum protein marker CST4 in China and the European Union, with 20 years of intellectual property protection, and the number of patents ranked second in this field in the Shanghai Free Trade Zone. We’ve completed the independent preparation of key raw materials such as antigens and antibodies required for the projects of CST4, Novel Coronavirus, and Alzheimer's Disease. Multiple underlying techniques of IVD have been developed and bottlenecks of mass production have been solved as well.


With the fully support of Academician Li Xiaokun's team, Shanghai Liangrun and Wenzhou Biomedicine Collaborative Innovation Center Co., Ltd. jointly established "Wenzhou Kunrun Biomedicine Technology Co., Ltd.", dedicating to promoting the development of emergency monitoring and diagnosis of major acute infectious diseases and cytokine abnormalities, exploring new models for the development of scientific research and industrial integration in medical colleges.


The registration certificates lists we’ve obtained for the product of “Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Test Kit (Colloidal Gold)” globally are showing below:





Consultation Hotline:
Contact information:(总机)021-50687977
Micro Channel Public Number:400-8208-195